Literature DB >> 24362721

Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients.

Vito Chiantera1, Martina Rossi, Pierandrea De Iaco, Christardt Koehler, Simone Marnitz, Anna Fagotti, Francesco Fanfani, Fabio Parazzini, Riccardo Schiavina, Giovanni Scambia, Achim Schneider, Giuseppe Filiberto Vercellino.   

Abstract

OBJECTIVE: Our study purpose was to evaluate morbidity and postoperative mortality in patients who underwent pelvic exenteration (PE) for primary or recurrent gynecological malignancies.
METHODS: We identified 230 patients who underwent PE, referred to the gynecological oncology units of 4 institutions: Charitè University in Berlin, Friedrich-Schiller University in Jena, S. Orsola-Malpighi University in Bologna, and Catholic University in Rome and in Campobasso.
RESULTS: The median age was 55 years. The tumor site was the cervix in 177 patients, the endometrium in 28 patients, the vulva in 16 patients, and the vagina in 9 patients. Sixty-eight anterior, 31 posterior, and 131 total PEs were performed in 116 women together with hysterectomy. A total of 82.6% of the patients required blood transfusion. The mean operative time was 446 (95-970) minutes, and the median hospitalization was 24 (7-210) days. We noted a major complication rate of 21.3% (n = 49). We registered 7 perioperative deaths (3%) calculated within 30 days. The operation was performed within clear margins in 166 patients (72.2%). The overall mortality rate depending on tumor site at the end of the study was 75% for vulvar cancer, 57.6% for cervical cancer, 55.6% for vaginal cancer, and 53.6% for endometrial cancer.
CONCLUSIONS: Although an important effort for surgeons and for patients, PE remains a therapeutic option with an acceptable complication rate and postoperative mortality. A strict selection of patients is mandatory to reach adequate surgical and oncologic outcomes.

Entities:  

Mesh:

Year:  2014        PMID: 24362721     DOI: 10.1097/IGC.0000000000000011

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  15 in total

Review 1.  Role of MR Imaging and FDG PET/CT in Selection and Follow-up of Patients Treated with Pelvic Exenteration for Gynecologic Malignancies.

Authors:  Yulia Lakhman; Stephanie Nougaret; Maura Miccò; Chiara Scelzo; Hebert A Vargas; Ramon E Sosa; Elizabeth J Sutton; Dennis S Chi; Hedvig Hricak; Evis Sala
Journal:  Radiographics       Date:  2015 Jul-Aug       Impact factor: 5.333

2.  Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015.

Authors:  H G Schnürch; S Ackermann; C D Alt; J Barinoff; C Böing; C Dannecker; F Gieseking; A Günthert; P Hantschmann; L C Horn; R Kürzl; P Mallmann; S Marnitz; G Mehlhorn; C C Hack; M C Koch; U Torsten; W Weikel; L Wölber; M Hampl
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10       Impact factor: 2.915

3.  Is a Vaginectomy Enough or is a Pelvic Exenteration Always Required for Surgical Treatment of Recurrent Cervical Cancer? A Propensity-Matched Study.

Authors:  Giuseppe Vizzielli; Lucia Tortorella; Carmine Conte; Vito Chiantera; Valerio Gallotta; Nazario Foschi; Martina Arcieri; Gabriella Ferrandina; Anna Fagotti; Filiberto Zattoni; Giovanni Scambia; Alfredo Ercoli
Journal:  Ann Surg Oncol       Date:  2020-10-15       Impact factor: 5.344

4.  Initial experience of laparoscopic pelvic exenteration and comparison with conventional open surgery.

Authors:  Keisuke Uehara; Hayato Nakamura; Yasushi Yoshino; Atsuki Arimoto; Takehiro Kato; Yukihiro Yokoyama; Tomoki Ebata; Masato Nagino
Journal:  Surg Endosc       Date:  2015-03-21       Impact factor: 4.584

5.  Perioperative Hyperglycemia and Glucose Variability in Gynecologic Laparotomies.

Authors:  Jorinde A W Polderman; Markus W Hollmann; J Hans DeVries; Benedikt Preckel; Jeroen Hermanides
Journal:  J Diabetes Sci Technol       Date:  2015-07-21

6.  Gynecologic Oncology: Pelvic Exenteration for Advanced or Recurring Cervical Cancer - A Single Center Analysis.

Authors:  Luisa Ter Glane; Axel Hegele; Uwe Wagner; Jelena Boekhoff
Journal:  Cancer Diagn Progn       Date:  2022-05-03

7.  Defining the concept of locally advanced squamous cell carcinoma of the vulva: a new perspective based on standardization of criteria and current evidence.

Authors:  Alejandro M Aragona; Alejandro H Soderini; Nicasio A Cuneo
Journal:  J Gynecol Oncol       Date:  2014-07-06       Impact factor: 4.401

8.  A surgical multi-layer technique for pelvic reconstruction after total exenteration using a combination of pedicled omental flap, human acellular dermal matrix and autologous adipose derived cells.

Authors:  Anna Myriam Perrone; Alessandra Livi; Milena Fini; Elena Bondioli; Sergio Concetti; Alessio Giuseppe Morganti; Federico Contedini; Pierandrea De Iaco
Journal:  Gynecol Oncol Rep       Date:  2016-10-27

9.  Pelvic exenteration by robotically-assisted laparoscopy: A feasibility series of 6 cases.

Authors:  Huyên-Thu Nguyen Xuan; Deloménie Myriam; Ngo Charlotte; Douard Richard; Bats Anne-Sophie; Timsit Marc Olivier; Méjean Arnaud; Lécuru Fabrice
Journal:  Gynecol Oncol Rep       Date:  2018-05-29

10.  Disease-free survival after robotic-assisted laparoscopic total pelvic exenteration for recurrent cervical adenocarcinoma: A case report.

Authors:  Qiyu Yang; Junying Tang; Lin Xiao
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.